

Roy F Chemaly

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2527422/publications.pdf>

Version: 2024-02-01

73
papers

5,197
citations

109264

35
h-index

88593

70
g-index

74
all docs

74
docs citations

74
times ranked

5520
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium. <i>Clinical Microbiology and Infection</i> , 2023, 29, 44-50.	2.8	16
2	Combination of baloxavir and oseltamivir for treatment of severe influenza infection in hematopoietic cell transplant recipients: a novel treatment strategy for a high-risk population. <i>Microbes and Infection</i> , 2022, 24, 104895.	1.0	4
3	Predicting risk of progression to lower respiratory tract infection in allogeneic hematopoietic cell transplant recipients with respiratory viral infections: where are we now?. <i>Bone Marrow Transplantation</i> , 2022, 57, 701-702.	1.3	1
4	How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies. <i>Blood</i> , 2022, 140, 673-684.	0.6	20
5	Cost-effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective. <i>Journal of Medical Virology</i> , 2021, 93, 3786-3794.	2.5	14
6	Varicella zoster immune globulin (human) (VARIZIG) in immunocompromised patients: a subgroup analysis for safety and outcomes from a large, expanded-access program. <i>BMC Infectious Diseases</i> , 2021, 21, 46.	1.3	12
7	Emergence and Transmission of Daptomycin and Vancomycin-Resistant Enterococci Between Patients and Hospital Rooms. <i>Clinical Infectious Diseases</i> , 2021, 73, 2306-2313.	2.9	12
8	Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. <i>Lancet Haematology</i> , 2021, 8, e185-e193.	2.2	271
9	Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era. <i>Clinical Infectious Diseases</i> , 2021, 73, 1346-1354.	2.9	43
10	The ever-growing world of infections in immunocompromised patients: major headways with numerous shortcomings. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1379-1380.	2.8	1
11	Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2710-2719.	0.8	32
12	American Society for Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 957-967.	0.6	26
13	Surveillance and identification of clusters of healthcare workers with coronavirus disease 2019 (COVID-19): Multidimensional interventions at a comprehensive cancer center. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 797-802.	1.0	15
14	Clinical and economic burden of preemptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients. <i>Journal of Medical Virology</i> , 2020, 92, 86-95.	2.5	20
15	A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2020, 71, 2777-2786.	2.9	53
16	Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials. <i>Clinical Infectious Diseases</i> , 2019, 68, 1420-1426.	2.9	136
17	Outcomes in Invasive Pulmonary Aspergillosis Infections Complicated by Respiratory Viral Infections in Patients With Hematologic Malignancies: A Case-Control Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz247.	0.4	24
18	Active Mycobacterium tuberculosis infection at a comprehensive cancer center, 2006-2014. <i>BMC Infectious Diseases</i> , 2019, 19, 934.	1.3	9

#	ARTICLE	IF	CITATIONS
19	In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: A systematic literature review. <i>Antiviral Research</i> , 2019, 163, 50-58.	1.9	64
20	Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies. <i>Haematologica</i> , 2019, 104, 1322-1331.	1.7	39
21	Reply to Jain et al. <i>Clinical Infectious Diseases</i> , 2019, 69, 2235-2236.	2.9	0
22	Refinement of estimates of mortality risk using the Radiologic Severity Index in hematologic malignancy patients with respiratory syncytial virus infection. <i>Transplant Infectious Disease</i> , 2019, 21, e13105.	0.7	3
23	Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2019, 68, 1641-1649.	2.9	71
24	Reply to Giménez et al. <i>Journal of Infectious Diseases</i> , 2019, 219, 1512-1513.	1.9	0
25	A Systematic and Critical Review of Bacteriophage Therapy Against Multidrug-resistant ESKAPE Organisms in Humans. <i>Clinical Infectious Diseases</i> , 2019, 69, 167-178.	2.9	106
26	Pulmonary Impairment after Respiratory Viral Infections Is Associated with High Mortality in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 800-809.	2.0	22
27	The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2019, 219, 898-907.	1.9	52
28	Influenza in patients with hematological malignancies: Experience at two comprehensive cancer centers. <i>Journal of Medical Virology</i> , 2018, 90, 50-60.	2.5	25
29	1561. Outcomes of Resistant or Refractory CMV Infection in Recipients of Allogeneic Hematopoietic Cell Transplant. <i>Open Forum Infectious Diseases</i> , 2018, 5, S486-S486.	0.4	2
30	Risk factors for mortality after respiratory syncytial virus lower respiratory tract infection in adults with hematologic malignancies. <i>Transplant Infectious Disease</i> , 2018, 20, e12994.	0.7	26
31	Update on infection control practices in cancer hospitals. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 340-355.	157.7	45
32	Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 931-941.	1.3	17
33	Antiviral therapy for respiratory viral infections in immunocompromised patients. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 401-415.	2.0	26
34	Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 512-521.	2.0	123
35	Burden of human metapneumovirus infections in patients with cancer: Risk factors and outcomes. <i>Cancer</i> , 2017, 123, 2329-2337.	2.0	25
36	Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2017, 377, 2433-2444.	13.9	796

#	ARTICLE	IF	CITATIONS
37	Evaluation of a pulsed xenon ultraviolet disinfection system to decrease bacterial contamination in operating rooms. <i>BMC Infectious Diseases</i> , 2017, 17, 672.	1.3	38
38	How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. <i>Blood</i> , 2016, 128, 2624-2636.	0.6	140
39	Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience. <i>Antiviral Research</i> , 2016, 134, 58-62.	1.9	37
40	Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series. <i>Antiviral Research</i> , 2016, 135, 91-96.	1.9	20
41	The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. <i>Cancer</i> , 2016, 122, 2186-2196.	2.0	121
42	Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review. <i>Cancer Letters</i> , 2016, 379, 100-106.	3.2	56
43	Parainfluenza virus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review. <i>Cancer Letters</i> , 2016, 370, 358-364.	3.2	86
44	Utility of the Enzyme-Linked Immunospot Interferon- γ Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2016, 213, 1701-1707.	1.9	63
45	Outcomes of Influenza Infections in Hematopoietic Cell Transplant Recipients: Application of an Immunodeficiency Scoring Index. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 542-548.	2.0	68
46	Non-inferiority of pulsed xenon UV light versus bleach for reducing environmental <i>Clostridium difficile</i> contamination on high-touch surfaces in <i>Clostridium difficile</i> infection isolation rooms. <i>Journal of Medical Microbiology</i> , 2015, 64, 191-194.	0.7	20
47	Infection Control Practices in Patients With Hematological Malignancies and Multidrug-Resistant Organisms: Special Considerations and Challenges. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S104-S110.	0.2	21
48	The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. <i>Journal of Oncology Pharmacy Practice</i> , 2014, 20, 257-262.	0.5	4
49	The Use of Fidaxomicin for Treatment of Relapsed <i>Clostridium difficile</i> Infections in Patients with Cancer. <i>Pharmacotherapy</i> , 2014, 34, 1220-1225.	1.2	17
50	Cytomegalovirus diseases after hematopoietic stem cell transplantation: A mini-review. <i>Cancer Letters</i> , 2014, 342, 1-8.	3.2	153
51	Perioperative Antimicrobial Prophylaxis for Intra-abdominal Surgery in Patients with Cancer: A Retrospective Study Comparing Ertapenem and Nonertapenem Antibiotics. <i>Annals of Surgical Oncology</i> , 2014, 21, 513-519.	0.7	15
52	Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2014, 370, 1781-1789.	13.9	315
53	Management of Respiratory Viral Infections in Hematopoietic Cell Transplant Recipients and Patients With Hematologic Malignancies. <i>Clinical Infectious Diseases</i> , 2014, 59, S344-S351.	2.9	172
54	Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections. <i>Blood</i> , 2014, 123, 3263-3268.	0.6	110

#	ARTICLE	IF	CITATIONS
55	Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1872-1880.	1.3	125
56	An Adaptive Randomized Trial of an Intermittent Dosing Schedule of Aerosolized Ribavirin in Patients With Cancer and Respiratory Syncytial Virus Infection. <i>Journal of Infectious Diseases</i> , 2012, 206, 1367-1371.	1.9	52
57	Characteristics and Outcomes of Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infections in Patients with Cancer Treated with Vancomycin: 9-Year Experience at a Comprehensive Cancer Center. <i>Oncologist</i> , 2012, 17, 1329-1336.	1.9	45
58	The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. <i>Blood</i> , 2012, 119, 2738-2745.	0.6	106
59	Antimicrobial Stewardship in Patients with Cancer. <i>Pharmacotherapy</i> , 2012, 32, 722-734.	1.2	46
60	A multicenter study of pandemic influenza A (H1N1) infection in patients with solid tumors in 3 countries. <i>Cancer</i> , 2012, 118, 4627-4633.	2.0	62
61	<i>Serratia marcescens</i> bacteremia because of contaminated prefilled heparin and saline syringes: A multi-state report. <i>American Journal of Infection Control</i> , 2011, 39, 521-524.	1.1	18
62	Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 284-292.	4.6	315
63	Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. <i>Blood</i> , 2011, 117, 2755-2763.	0.6	225
64	Characteristics and Outcomes of Methicillin-Resistant <i>Staphylococcus aureus</i> Surgical-Site Infections in Patients with Cancer: a Case-Control Study. <i>Annals of Surgical Oncology</i> , 2010, 17, 1499-1506.	0.7	23
65	Valacyclovir: approved and off-label uses for the treatment of herpes virus infections in immunocompetent and immunocompromised adults. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1901-1913.	0.9	12
66	Palivizumab: where to from here?. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 139-147.	1.4	24
67	Herpes simplex virus lower respiratory tract infection in patients with solid tumors. <i>Cancer</i> , 2009, 115, 199-206.	2.0	20
68	Neuraminidase Inhibitors Improve Outcome of Patients with Leukemia and Influenza: An Observational Study. <i>Clinical Infectious Diseases</i> , 2007, 44, 964-967.	2.9	55
69	Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia. <i>Haematologica</i> , 2007, 92, 1216-1223.	1.7	55
70	Viral infection or reactivation in patients during treatment with dasatinib: A call for screening?. <i>Leukemia and Lymphoma</i> , 2007, 48, 2308-2309.	0.6	8
71	Respiratory Viral Infections in Adults With Hematologic Malignancies and Human Stem Cell Transplantation Recipients. <i>Medicine (United States)</i> , 2006, 85, 278-287.	0.4	297
72	Cytomegalovirus pneumonia in patients with lymphoma. <i>Cancer</i> , 2005, 104, 1213-1220.	2.0	50

#	ARTICLE	IF	CITATIONS
73	Microbiology of liver abscesses and the predictive value of abscess gram stain and associated blood cultures. <i>Diagnostic Microbiology and Infectious Disease</i> , 2003, 46, 245-248.	0.8	52